The Division of Rheumatology strives to understand more about scleroderma and systemic sclerosis through research. Please see the list below, which summarizes the studies available to individuals interested in advancing our understanding and treatment of rheumatic disease.
Study Name/IRB#/PI | Brief Description | Basic Eligibility Criteria | Contact |
Scleroderma Lung Study III (SLS III) 17-1226 | The purpose of the study is to research a new treatment for Scleroderma related lung disease (ILD). | To qualify for study participation, you must be:
| 303-724-0581; or email Mallary Crow Adams |
Systemic Sclerosis (JBT-101) 17-1792 | The purpose of the study is to research Lenabasum (JBT-101), an experimental drug that may reduce inflammation and stop the development of scar tissue, also called fibrosis, which results from chronic active inflammation. | To qualify for study participation, you must be:
| 303-724-0581; or email Mallary Crow Adams |
Please note that study status changes frequently and therefore, a listed study may not be actively enrolling. Also, the complete list of inclusion and exclusion criteria for a given study is often not listed due to its length. A visit to determine an individuals eligibility may be required. A placebo is an inactive substance or treatment that looks the same as, and is given the same way as, an active drug or treatment being tested. The effects of the active drug or treatment are compared to the effects of the placebo.